Novel synthetic method for tadalafil
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ZHEJIANG YONGNING PHARMA
- Publication Date
- 2016-02-24
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention relates to a synthesis method of compounds in the technical field of medicine and chemical engineering, in particular to a synthesis method of tadalafil. Background technique
[0002] The chemical name of tadalafil is (6R-12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a - Hexahydropyrazino[1',2'-1,6]-pyrido[3,4-b]indole-1,4-dione, the structural formula is as follows:
[0003]
[0004] Tadalafil is a phosphodiesterase type V (PDE5) inhibitor. When sexual stimulation leads to the local release of nitric oxide, PDE5 is inhibited by tadalafil, which increases the level of cyclic guanosine monophosphate in the cavernous body of the penis, which leads to Smooth muscles relax and blood flows into the penile tissue, producing an erection. The compound was originally developed by GlaxoSmithKline and subsequently transferred to ICOS, and later jointly developed by ICOS and Eli Lilly. Approved by the FDA in 2003, tadalafil was listed in...